DoD Kidney Cancer, Concept Award
ID: 355136Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355136
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Kidney Cancer Research Program (KCRP) Concept Award to support innovative research in kidney cancer. This grant aims to fund high-risk, groundbreaking studies that do not require preliminary data, focusing on novel concepts that can enhance understanding of kidney cancer biology and improve therapeutic strategies and patient outcomes. With an estimated total program funding of $1.44 million, the program anticipates awarding approximately nine grants, each with a maximum direct cost of $100,000 for a one-year period. Interested applicants must submit a pre-application letter of intent by August 15, 2024, and full applications by September 5, 2024. For further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.

    Point(s) of Contact
    help@@ebrap.org
    Files
    Title
    Posted
    HT942524KCRPCA_GG_Final.pdf
    The DOD FY24 Kidney Cancer Concept Award program aims to support innovative research in kidney cancer through funding by the Department of Defense's Defense Health Program. The program invites applications relevant to active-duty military personnel, veterans, and the general public, with a total appropriation of $50 million for fiscal year 2024. Important submission deadlines include a pre-application letter of intent by August 15, 2024, and full applications due by September 5, 2024. The Concept Award specifically encourages high-risk, groundbreaking studies without requiring preliminary data. It focuses on understanding kidney cancer biology, developing therapeutic strategies, and improving patient care outcomes. Eligible applicants include a wide range of organizations, and the total direct costs should not exceed $100,000 over one year. The review process involves a two-tier evaluation by scientists, clinicians, and programmatic experts, ensuring that applications align with the program's strategic goals. This funding opportunity emphasizes collaborations across fields and organizations, including military, academic, and industry partnerships, reinforcing the mission to advance kidney cancer research for better patient impact and care. Applicants are urged to familiarize themselves with the KCRP Strategic Plan to align their proposals with overarching goals and priorities.
    Similar Opportunities
    NCI Continuing Umbrella of Research Experiences (CURE) Mentored Clinical Scientist Research Career Development Award (K08 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NCI Continuing Umbrella of Research Experiences (CURE) Mentored Clinical Scientist Research Career Development Award (K08), aimed at fostering diversity within the cancer research workforce. This grant supports clinical scientists with doctoral degrees who are underrepresented in health-related research, providing salary support for a 3-5 year period to gain intensive research training in various cancer research fields, particularly focusing on health disparities. The program is designed to enhance the research capabilities of awardees, preparing them for independent research careers in basic biomedical, behavioral, or translational cancer research. Interested applicants should note that the application period opens on January 12, 2025, with a submission deadline of February 12, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-320.html.
    DOD Glioblastoma, Transformative Consortium Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Glioblastoma Transformative Consortium Award, aimed at advancing research to improve outcomes for glioblastoma patients. This grant seeks proposals for innovative, multidisciplinary projects that collectively address a central hypothesis, requiring collaboration among at least four distinct projects and the inclusion of a consumer advocate. With an estimated total program funding of $9 million, the application process includes a pre-application deadline of December 23, 2024, and a full application deadline of January 13, 2025. Interested applicants can reach the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507 for further assistance.
    NCI Continuing Umbrella of Research Experiences (CURE) Mentored Clinical Scientist Research Career Development Award (K08 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NCI Continuing Umbrella of Research Experiences (CURE) Mentored Clinical Scientist Research Career Development Award (K08), aimed at training individuals with clinical doctoral degrees for impactful careers in health-related research, particularly in cancer studies. This program is designed to support individuals from underrepresented backgrounds in health-related sciences, providing them with a mentored research career development experience over a period of 3 to 5 years, focusing on biomedical, behavioral, and clinical research, including clinical trials. Successful applicants are expected to commit at least 75% of their time to the project and will receive funding for salary and research-related expenses, with applications due at specific intervals starting January 12, 2025. For further information, interested parties can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-319.html.
    NCI Continuing Umbrella of Research Experiences (CURE) Non-Mentored Research Scientist Career Development Award (K22 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NCI Continuing Umbrella of Research Experiences (CURE) Non-Mentored Research Scientist Career Development Award (K22), aimed at supporting senior postdoctoral fellows in their transition to independent research roles. This grant specifically targets candidates from diverse backgrounds, with the objective of fostering an inclusive research workforce and enhancing cancer research capabilities. The K22 award provides three years of salary and research funding, encouraging the development of independent research projects, particularly those leading to clinical trials. Interested applicants must adhere to NIH guidelines and submit their applications by January 7, 2028, with further details available at NIH Grants. For inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed)." This initiative aims to support the development of innovative tools and technologies that address significant challenges in kidney, urologic, and hematologic research, encouraging high-risk, exploratory projects that differ from traditional R01 grants. The funding, with a maximum budget of $275,000 over two years, is open to a diverse range of eligible applicants, including various educational institutions and community organizations, with applications due by January 7, 2025. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-23-119.html.
    NCI Small Grants Program for Cancer Research (NCI Omnibus) (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the NCI Small Grants Program for Cancer Research (R03), aimed at supporting short-term cancer research projects that require limited resources. This funding opportunity encourages diverse research efforts, including pilot studies, secondary data analyses, and the development of research methodologies, with a maximum budget of $50,000 per year for projects lasting up to two years. The program is designed to address significant knowledge gaps in cancer research and is open to a wide range of applicants, including public, private, and foreign entities. Interested parties should note that the application period opens on January 24, 2025, with a submission deadline of February 24, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Paul Calabresi Career Development Award for Clinical Oncology (K12), aimed at supporting institutional research career development programs for clinical scientists in cancer research. This initiative emphasizes training for clinical scientists who aspire to lead independent clinical trials or contribute to existing trials, thereby enhancing the field of clinical cancer research. The NOFO is anticipated to be released in November 2024, with the first application deadline set for February 2025, and the estimated award date is January 5, 2026. Interested applicants are encouraged to begin developing collaborations and applications in advance, as there are no cost-sharing requirements associated with this grant opportunity.
    Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)." This initiative aims to support exploratory research projects that focus on the early-stage development of innovative technologies for molecular and cellular analysis in cancer research, with an emphasis on enhancing characterization of cancer biology and addressing health disparities. Eligible applicants include a wide range of organizations, such as higher education institutions, non-profits, and tribal governments, with funding available up to $150,000 annually for a project period not exceeding three years. The total estimated funding for this program is approximately $4.2 million, with about 17 awards expected to be made. Interested applicants can find more information and submit inquiries via email to grantsinfo@nih.gov, with applications due by October 3, 2025.
    NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the NCI Small Grants Program for Cancer Research (R03) for the years 2023 to 2025. This funding opportunity is designed to support small-scale research projects on cancer that can be completed within a two-year timeframe and with limited resources, including pilot studies, secondary data analyses, and the development of research methodologies or technologies. Grants of up to $50,000 per year are available to a wide range of eligible applicants, including higher education institutions, nonprofits, and various community organizations. Interested parties should submit their applications electronically via Grants.gov, with the first submission deadline having been January 22, 2023, and subsequent deadlines continuing through 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NCI Continuing Umbrella of Research Experiences (CURE) Non-Mentored Research Scientist Career Development Award (K22 Independent Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NCI Continuing Umbrella of Research Experiences (CURE) Non-Mentored Research Scientist Career Development Award (K22), aimed at supporting diverse candidates transitioning from postdoctoral roles to independent research positions in cancer research. This grant provides financial support for up to three years, covering salary and research costs, specifically targeting senior postdoctoral fellows and individuals in equivalent positions who have completed relevant training and hold early-stage investigator status. The initiative emphasizes the importance of diversity in the biomedical workforce, encouraging applications from underrepresented groups, while stipulating that candidates cannot lead their own clinical trials but may participate in trials led by mentors. Interested applicants should note that the application deadline is January 7, 2028, and can find further details and guidelines in the full announcement available at NIH Grants. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.